Gland Pharma stock price down by more than 4% today

30 Nov 2022 , 02:18 PM

Following the company’s entry into a Put Option Agreement to purchase 100% of Cenexi Group for an equity value not exceeding Euro 120 million on Wednesday, Gland Pharma’s shares fell 5% to Rs 1,787.55 on the BSE (Enterprise Value of Euro 230 million).

Through its wholly-owned Singaporean subsidiary Gland Pharma International PTE. Ltd., Gland Pharma will purchase Cenexi Group. Cenexi reported yearly sales of 184.1 million euros in CY21 and an Ebitda of 23.1 million euros; in H1CY22, the exact figures were 100.1 million euros and 19.1 million euros, respectively. Earnings Before Interest, Tax, Depreciation, and Amortization, or Ebitda, is what is referred to.

In the last three months, Gland Pharma’s stock price has decreased by 25%, while the S&P BSE Sensex has increased by 5.4%. Furthermore, it has lost 50% of its value in the last year compared to the benchmark index’s 10% rally. On November 10, 2022, the stock dropped to an all-time low of Rs 1,660. On August 12, 2021, it reached its highest point of Rs 4,350.

For feedback and suggestions, write to us at [e-mail]